Result of AGM

RNS Number : 3240U

Advanced Oncotherapy PLC

29 July 2022

 

29 July 2022

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Result of AGM

Advanced Oncotherapy (AIM:AVO), the developer of LIGHT, the next-generation proton therapy system for cancer treatment, announces that at the Annual General Meeting (AGM) held earlier today, all resolutions were passed. The results of the proxy voting for the AGM are set out below:

Resolution	Total votes For 1	% of votes cast 2	Total Votes Against	% of votes cast 2	Votes Withheld 3
1. To receive the audited financial statements and the Auditor's and Directors reports for the year ended 31 December 2021	186,380,372	88.84	23,401,405	11.16	8,237
2. To re-appoint Michael Bradfield as a Director of the Company	209,005,437	99.63	777,004	0.37	7,573
3. To re-appoint Hans von Celsing as a Director of the Company	186,340,437	88.84	23,402,004	11.16	7,573
4. To re-appoint Lori Cross as a Director of the Company	208,965,437	99.63	777,004	0.37	7,573
5. To re-appoint Prof. Steve Myers as a Director of the Company	209,005,437	99.63	777,004	0.37	7,573
6. To re-appoint Dr Nick Plowman as a Director of the Company	208,965,437	99.63	777,004	0.37	7,573
7. To re-appoint Nicolas Serandour as a Director of the Company	208,965,437	99.63	777,004	0.37	7,573
8. To re-appoint Dr Michael Sinclair as a Director of the Company	209,005,437	99.63	777,170	0.37	7,407
9. To re-appoint Dr Enrico Vanni as a Director of the Company	186,340,437	88.84	23,402,004	11.16	7,573
10. To re-appoint Renhua Zhang as a Director of the Company	208,965,437	99.63	777,004	0.37	7,573
11. To re-appoint RPG Crouch Chapman LLP as Auditors of the Company	178,595,773	85.13	31,186,834	14.87	7,407
12. To authorise the Directors to determine the remuneration of the Auditors	208,998,603	99.63	781,504	0.37	9,907
13. That the Directors be authorised to allot shares and/or to grant rights to subscribe for, or to convert any securities into shares in the Company	208,778,437	99.52	1,001,670	0.48	9,907
14. That, subject to Resolution 13, the Directors be empowered to allot equity securities as if section 561 of the Act did not apply	186,025,264	88.68	23,754,677	11.32	9,907

Notes

1.  Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution

2.  Percentage of votes cast excludes Votes Withheld

3.  Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution

- ENDS -

Advanced Oncotherapy plc	www.avoplc.com
Dr. Michael Sinclair, Executive Chairman	Tel: [phone]
Nicolas Serandour, CEO
Allenby Capital Limited (Nomad and Joint Broker)
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking)	Tel: [phone]
SI Capital Ltd (Joint Broker)
Nick Emerson	Tel: [phone]
Jon Levinson	Tel: [phone]
FTI Consulting (Financial PR & IR)	[e-mail]
Simon Conway / Rob Winder	Tel: [phone]

About Advanced Oncotherapy Plc

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

RAGSEMFIUEESEEW